Calculateur du score original de Glasgow pour l’hépatite alcoolique à l’admission/au jour 1

État

clinical-review-pending

Version de la méthode

Forrest 2005 original admission/day-1 Glasgow Alcoholic Hepatitis Score arithmetic v1: age <50 years = 1 point and >=50 = 2; peripheral white-cell count <15 ×10^9/L = 1 and >=15 = 2; blood urea (whole urea, not BUN) <5 mmol/L = 1 and >=5 = 2; prothrombin-time ratio to the reporting-laboratory control <1.5 = 1, 1.5 through 2.0 inclusive = 2, and >2.0 = 3; total serum bilirubin <125 µmol/L = 1, 125 through 250 inclusive = 2, and >250 = 3. The raw integer total is the sum of the five component points and ranges from 5 through 12. All values must come from the same admission/day-1 assessment in the fixed source-native identities and units; no unit conversion is performed. The PT ratio is the dimensionless patient PT divided by the matched control used by the reporting laboratory; INR, patient PT seconds, control PT seconds alone, and another laboratory's ratio are not accepted. The distinct days-6–9/day-7 assessment and all interpretive cutoff, category, outcome, mortality, survival, prognostic, diagnostic, severity, treatment, recommendation, or management logic are excluded.

Population

Adults for whom applicability of the original Forrest 2005 UK alcoholic-hepatitis source setting is independently established, including recent alcohol excess and admission total serum bilirubin >=80 µmol/L. The derivation cohort comprised 241 patients presenting to two Glasgow hospitals, and the validation cohort comprised 195 patients from eight UK hospitals. Age, peripheral white-cell count, blood urea, prothrombin-time ratio, and total serum bilirubin must be complete verified source-native values from the same admission/day-1 assessment; the PT ratio must use the matched control of the reporting laboratory, with analyte, specimen, method, unit, control, source-value, and timing identities independently verified. The source cohorts were heterogeneous in clinical-versus-biopsy ascertainment and other enrollment criteria and were not treated with corticosteroids or pentoxifylline. Applicability and transportability must be assessed independently; this arithmetic does not diagnose alcohol-associated hepatitis.

Limites et exclusions

The source paper's published total-score cutoff, result or severity category, individual outcome, mortality or survival estimate, prognostic classification or statement, diagnosis or confirmation, corticosteroid or other treatment eligibility, treatment selection, recommendation, management, or any other clinical decision. · The distinct days-6–9/day-7 GAHS assessment, a mixed-time-point score, substitution of follow-up values for admission/day-1 values, or combining values from different admissions, episodes, laboratories, or assessment times. · Substitution of INR, patient PT seconds, control PT seconds alone, a PT ratio based on another laboratory's control, BUN for whole urea, bilirubin in mg/dL, or any inferred or converted value for the fixed source-native input identities and units. · Missing, inferred, imputed, default-normal, carried-forward, rounded-before-scoring, nonquantitative, or otherwise unverified inputs; altered component boundaries, weights, or total arithmetic. · Pediatric use or use outside the original adult UK source setting, recent-alcohol-excess context, and admission bilirubin >=80 µmol/L boundary without an independent assessment of applicability and transportability; extrapolation to another liver disease, population, endpoint, or laboratory workflow.

• https://pubmed.ncbi.nlm.nih.gov/16009691/
• https://doi.org/10.1136/gut.2004.050781
• https://pmc.ncbi.nlm.nih.gov/articles/PMC1774903/

Outil importé de la bibliothèque PharmaTek de MDose. Aucune date de révision clinique indépendante n’est documentée dans cette version.

Bibliothèque source

PharmaTek · MDose

Version importée

4b66536936ed

État de publication

Révision clinique en cours